Supernus Pharmaceuticals (SUPN) Gross Profit (2013 - 2025)

Supernus Pharmaceuticals (SUPN) has 13 years of Gross Profit data on file, last reported at $188.6 million in Q4 2025.

• On a quarterly basis, Gross Profit rose 27.36% year-over-year to $188.6 million in Q4 2025; TTM through Dec 2025 was $644.4 million, a 10.36% increase from a year earlier, with the FY2025 full-year figure at $644.4 million, up 10.36% from the prior year.
• Gross Profit for Q4 2025 stood at $188.6 million, up from $173.1 million in the prior quarter.
• Over the last five years, Gross Profit for SUPN reached as high as $188.6 million in Q4 2025 and fell as low as $114.5 million in Q2 2023.
• Historically, Gross Profit has averaged $141.8 million across 5 years, with a median of $143.2 million in 2021.
• Across the five-year window, Gross Profit decreased 23.48% in 2023 and soared 31.39% in 2024, its largest moves.
• Year by year, Gross Profit stood at $142.1 million in 2021, then climbed by 1.63% to $144.4 million in 2022, then grew by 0.22% to $144.7 million in 2023, then advanced by 2.33% to $148.1 million in 2024, then increased by 27.36% to $188.6 million in 2025.
• Per Business Quant data, the three most recent Gross Profit figures were $188.6 million in Q4 2025, $173.1 million in Q3 2025, and $148.6 million in Q2 2025.